The Sicilian Step Forward on Celiac Disease MEDICEL Meeting Palermo, 2014 April 26 th.

Slides:



Advertisements
Similar presentations
Diagnostic Work-up. There is no specific laboratory or imaging test to diagnose irritable bowel syndrome. Currently the diagnosis of IBS relies on meeting.
Advertisements

Recognition and assessment of coeliac disease Implementing NICE guidance 2009 NICE clinical guideline 86.
Celiac disease in Slovenia
The “Great Mimic” Disease
A.M. Report 5/5/09 Jason Haag, M.D.
1 Literature Review Peter R. McNally, DO, FACP, FACG University of Colorado School of Medicine, Center for Human Simulation Aurora, Colorado
Unit 6 Diagnosis & Follow-up of HIV Infection
Does early Computerised Tomography exclude fracture in ‘Clinical Scaphoid Fracture’? Dr. Mark Harris Dr Jaycen Cruickshank Department of Orthopaedics,
Studying a Study and Testing a Test: Sensitivity Training, “Don’t Make a Good Test Bad”, and “Analyze This” Borrowed Liberally from Riegelman and Hirsch,
Definition. Celiac disease is an immune-mediated enteropathycaused by a permanent sensitivity to gluten in genetically susceptible individuals. It occurs.
Celiac disease Prepared by :Maha Hmeidan nahal.
Raanan Shamir, MD Cost Effectiveness of Population Screening
Dr Nader Ghaderi, GPR. General information First described in ancient Greek by Aretaeus of Cappadocia The word Coeliac was first used in 19 th century.
The prospective study and the new ESPGHAN protocol L. Greco, D. Mičetić-Turk Mediterranean Network for Celiac Disease Istanbul, June 30th 2012.
Prof. Dr. Giuseppe Magazzu Prof. Dr. Dušanka Mičetić-Turk and all Progress of the Prospective study - Medicel.
…………. Aydan Kansu, MD Ankara University School of Medicine, Department of Pediatric Gastroenterology and Hepatology, Turkey.
© 2014 SynteractHCR. All rights reserved. SHARED WORK. SHARED VISION. Pitfalls in Companion Diagnostics Don't underestimate the power of conditional probabilities.
Coeliac Disease Eileen Parrott. Very common. We all miss opportunities to diagnose. At least 1% of population. Runs in families. Peak incidence currently.
SCREENING FOR CELIAC DISEASE IN EGYPTIAN CHILDREN SCREENING FOR CELIAC DISEASE IN EGYPTIAN CHILDREN Prof. Dr: Mona Abu Zekry -Professor of Pediatrics Head.
Dr Catherine Taylor GPST2 Familial Hypercholesterolaemia.
Celiac Disease in Children Dascha C. Weir, MD Boston Children’s Hospital Harvard Medical School Gluten Free for Life Conference April 11, 2015.
Clinical Presentation of Celiac Disease Alessio Fasano, M.D. Mucosal Immunology and Biology Research Center And Center for Celiac Research – Celiac Program.
The near future, applications and activities G. Magazzù and L. Greco.
Celiac Disease and Diabetes Marian Rewers, MD, PhD Professor & Clinical Director University of Colorado, School of Medicine.
Celiac Disease Ryan Sanford 3/30/10.
Eat to Heal... the Cure is Food!. Overview  Celiac Disease Definition Symptoms and presentations Diagnosis Treatment  The Kogan Celiac Center at Barnabas.
Irritable Bowel Syndrome Sam Thomson 3 rd November 2010.
The Mediterranean Network for the management of food induced diseases WORKSHOP MEDI-CEL The Mediterranean Network for Celiac Disease V Progress Meeting.
Journal Club 30/09/05 V Dory GP treatment decisions for patients with depression: an observational study Kendrick T, King F, Albertella L, Smith P Br J.
Upper GI 2WW referrals & open access endoscopy Dr Amanda J Hughes.
What are we talking about? Functional gastrointestinal disorders (FGIDs) are defined as a variable combination of chronic or recurrent gastrointestinal.
Prospective Study Cohort Study Assis.Prof.Dr Diaa Marzouk Community Medicine.
4. Department of Psychiatry, Johns Hopkins School of Medicine
Department of General Practice Aarhus University Diagnostic delay in cancer in primary health care Before and after introducing urgent referrals for suspected.
Coeliac disease NICE Clinical Guideline 86, May 2009.
Basic statistics 11/09/13.
Tuberculosis Research of INA-RESPOND on Drug-resistant
Statistics for Health Care Biostatistics. Phases of a Full Clinical Trial Phase I – the trial takes place after the development of a therapy and is designed.
SCREENING Asst. Prof. Sumattna Glangkarn RN, MSc. (Epidemiology), PhD (Nursing studies)
Screening and Diagnostic Testing Sue Lindsay, Ph.D., MSW, MPH Division of Epidemiology and Biostatistics Institute for Public Health San Diego State University.
Impact of the new ESPGHAN diagnostic criteria for celiac disease in the Mediterranean area The Mediterranean Network for Celiac Disease V Progress Meeting.
Screening for Celiac Disease In Rural Areas in Egypt Prof. Dr: Mona Abu Zekry Cairo University.
Prof. Dr. Giuseppe Magazzu Prof. Dr. Dušanka Mičetić-Turk and all Progress of the Prospective study - Medicel.
Screening Puja Myles
Celiac Disease.
Screening and its Useful Tools Thomas Songer, PhD Basic Epidemiology South Asian Cardiovascular Research Methodology Workshop.
1 Wrap up SCREENING TESTS. 2 Screening test The basic tool of a screening program easy to use, rapid and inexpensive. 1.2.
The Natural History of Undiagnosed Celiac Disease: A Retrospective Study Craig Sturgeon 1, Bushra Bhatti 1, Debby Kryszak 1, Carlo Catassi 1, Kathy Helzlsouer.
Indiaclen Short course of Amoxicillin in treatment of Pneumonia (ISCAP) 3 versus 5 days amoxicillin for treatment of non-severe pneumonia in young children:
Health care utilization patterns and economic consequences of TB Dr. K. Zaman ICDDR,B National TB Conference 2007, NATAB.
The First MEDICEL Meeting Cairo 30 th April to 1 st May 30 th April to 1 st May Prof. Luigi Greco Dr. Laura Timpone Following ESPGHAN PROTOCOL REVISION.
Coeliac Disease. What is Coeliac disease? Autoimmune Heightened immunological response to ingested GLUTEN In genetically susceptible people.
ESPGHAN COMMITTEE to revise the diagnostic protocol of Celiac Disease Prof. Riccardo Troncone, President March 2010.
Diagnosis and Treatment of Celiac Disease in Children
FIT Programme (Faecal Immunohistochemical Test)
Refer to Beds & Herts Breast Cancer Family History Screening service
Celiac Disease and Autoimmune Diseases
DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M
Evaluation of CT Coronary Angiography (CTCA) and Cardiac Magnetic Resonance (CMR) in patients presenting with Acute Chest Pain (ACP) at A&E Background.
An effective COPD case finding strategy in Primary Care
Coeliac Disease at ABCD
Refer to Beds & Herts Breast Cancer Family History Screening service
Associated Conditions
Hunter Syndrome: Why We Need to Diagnose and Treat Early
Rhematoid Rthritis Respiratory disorders
The prospective study and the new ESPGHAN protocol
Volume 153, Issue 2, Pages e17 (August 2017)
Features and Progression of Potential Celiac Disease in Adults
Colorectal 2 week wait pathways and “Getting FIT”
Presentation transcript:

The Sicilian Step Forward on Celiac Disease MEDICEL Meeting Palermo, 2014 April 26 th

Case finding vs screening in sequence to bridge the diagnostic gap of CD in Sicily Background: more than 2/3 of CD patients are not recognized yet with possible severe consequences in terms of morbidity, mortality ans costs Aims: Primary: to assess the yield of two strategies for diagnosing CD in Sicily SecondarySecondary: to assess the PPV of the PoCT to assess the compliance to GFD and quality of life between patients diagnosed by case finding or by screening

DESIGN AND SETTING: Design: two phase prospective study Settings: Family Pediatrician Office (FPO) Referral center for CD

PATIENTS AND METHODS Two phases study: 1st phase: prospective case finding during a 6-month period

SYMPTOMS TO LOOK FOR Gastrointestinal symptms in the first 2 years of life Chronic diarrhoe and Irritable bowel syndrome Dyspepsia Weight loss Iron deficiency anemia Short stature compared with genetic target IDDM Hashimoto Tyroiditis Other autommine or rheumatologic disorders Epilepsy treatment resistant or wih occipatl localization Ataxia and peripherale neuropathies Dermatitis herpetiformis, Vitiligo, Alopecia areata, Psoriasis Chronic Orticaria Sine causa hypertransaminasemia (AST/ALT > 2 uln x 3 months) Enemal dental changes Stomatitis (> 3 episods/year) I or II degree relatives with CD

PATIENTS AND METHODS Two phase study: 1 st phase: prospective case finding during a 6-month period and referred to Center All children visited during this period were recorded 2 nd phase: hypothesizing a CD prevalence at screening of 0,01 and of 0,005 at case finding, setting α error at 0.05 and β error at 0.90, sample size needed find significant difference between two strategies was Children recorded in the 1st phase negative at case finding were consecutively offered PoC test in the order they went to FPO until complete utilization of the kits assigned to FP Gold standard: Marsh 2-3 at histology or EMA

Population in charge Case finding for 6 months Suspected 790 (3.2%) Enrolled 678 Refusal 112 (14%) I tTG + 34 II tTG + 21 CD confirmed Ist. 2 no Ist DSG 1 lost F.U. 3 Marsh 0 1 Marsh 1 1 F.U. tTG 11 Not suspected Performed PoC 3559 Pos 111 No line 45 To Centre Ist o EMA + 17 N IgA 35 tTG-G pos. 3c tTG-A 42 EMA N- In F.U. Neg 89 Neg 3448 Pos 20 IgA Def. 9 Lost FU 1 FU 3 Refusal 2 tTG-A 122, EMA + Marsh 3c Offered PoC 3642 Refused 83 (2.3%)

By total By CF By SC Known Celiac 103 (1:303)(1:236) Celiac after CF 118 (1:265)(1:206) Celiac after SC 137(1:228)(1:177)(1:187) Yield of Case finding: 15 new CD out of 678 suspected (1:45) Yield of screening: 19 new CD out of 3559 screened (1:187) CF Yield/SC Yield = 4:1 Elisa tTG Cost/PoCT Cost 6:1 Additional costs for CF: those of the unrecognized CD Additional costs for SC: those of 1:42 false positive

Screening vs Case finding in parallel to bridge the diagnostic gap of CD in Sicily Background: more than 2/3 of CD patients are not recognized yet with possible severe consequences in terms of morbidity, mortality ans costs. PoCT would be the ideal test to use it provided that its NPV is accepptable Aims: Primary: to assess the yield of two strategies for diagnosing CD in Sicily when they are applied in parallel SecondarySecondary: to assess the NPV of the PoCT

DESIGN AND SETTING: Design: one phase prospective study Settings: Family Pediatrician (FP), General Practioner (GP) Office and Referral center for CD

PATIENTS AND METHODS 8000 consecutive subjects prospectively seen at FP (4000) and GP (4000) office with the only exclusion criteria being an already known diagnosis of CD or a previous serological test for CD in the last year. They are offered PoCT and then asked regarding the presence of one or more symptoms or signs of CD foreseen in a case- finding questionnaire

SYMPTOMS TO LOOK FOR Gastrointestinal symptms in the first 2 years of life Chronic diarrhoe and Irritable bowel syndrome Dyspepsia Weight loss Iron deficiency anemia Short stature compared with genetic target IDDM Hashimoto Tyroiditis Other autommine or rheumatologic disorders Epilepsy treatment resistant or wih occipatl localization Ataxia and peripherale neuropathies Dermatitis herpetiformis, Vitiligo, Alopecia areata, Psoriasis Chronic Orticaria Sine causa hypertransaminasemia (AST/ALT > 2 uln x 3 months) Enemal dental changes Stomatitis (> 3 episods/year) I or II degree relatives with CD

PATIENTS AND METHODS 8000 consecutive subjects prospectively seen at FP (4000) and GP (4000) office with the only exclusion criteria being an already known diagnosis of CD or a previous serological test for CD in the last year. They are offered PoCT and then asked regarding the presence of one or more symptoms or signs of CD foreseen in a case-finding questionnaire All cases with PoCT positive, doubt or no line and those positive at case finding questionnaire will be sent the referral Center

PoCT NegPos CF= Case finding. Patients of Group 3 who are referred to Center allow to calculate NPV of PoC